85
20.
Türkiye Kronik Viral Hepatit Taný ve Tedavi Rehberi 2015
21.
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological
gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.)
22.
Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National
Institutes of Health Consensus Development Conference Statement: management
of hepatitis B. Ann Intern Med. Jan 20 2009;150(2):104-10)
23.
Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and future
challenges. QJM. Feb 2012;105(2):109-13.
24.
Papatheodoridis GV, Cholongitas E, Archimandritis AJ, et al. Current management
of hepatitis B Lan infection before and after liver transplantation. Liver Int
2009;29:1294–1305.)
25.
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with
tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up
study. Lancet 2013; 381:468–475.
26.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update.
Hepatology 2011;53:1020–1022.
27.
EASL-EORTC clinical practice guidelines: management of hepatocellular
carcinoma. J Hepatol 2012;56:908–943.
28.
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of
the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int
2010;4:439–474.
29.
Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice.
Gastroenterology 2012;142:1360–1368, e1361.
30.
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and
the combination for HBeAg-positive chronic hepatitis B. N Engl J Med
2005;352:2682–2695.
31.
Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone,
and the two in combination in patients with HBeAg-negative chronic hepatitis B. N
Engl J Med 2004;351:1206–1217.)
32.
Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after
long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-
2b. Gastroenterology 2008;135:459–467.
33.
Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e
antigen-negative patients 3 years after treatment with peginterferon alpha-2a.
Gastroenterology 2009; 136:2169–2179, e2161–2164.
34.
Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients
with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Gastroenterology 2009; 137:2002–2009.
35.
Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone,
and the two in combination in patients with HBeAg-negative chronic hepatitis B. N
Engl J Med 2004; 351:1206–1217
36.
Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a
guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic
hepatitis B. Hepatology 2009;49:1141–1150.
37.
Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-
related hepatitis B surface antigen seroclearance in genotype D hepatitis B e
antigen-negative patients with chronic hepatitis B. Hepatology 2013;57:890–896.
38.
Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in
patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology
Kronik HBV Enfeksiyonunda Tedavi
